Eli Lilly to acquire Orna Therapeutics for up to $2.4bn.

Eli Lilly, a pharmaceutical company, agreed to acquire Orna Therapeutics, a biotechnology company, for up to $2.4bn. "Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost, and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them. We look forward to working with Orna colleagues to potentially unlock an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options," Francisco Ramírez-Valle, Eli Lilly Senior Vice President, Head of Immunology Research and Early Clinical Development.